Xenon Pharmaceuticals (XENE) Income from Continuing Operations (2013 - 2026)
Xenon Pharmaceuticals' (XENE) quarterly Income from Continuing Operations came in at 102302000.0 in Q1 2026, down 57.27% year-on-year from 239437183.15 in Q1 2025, and up 10.75% on a QoQ basis from 114630000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Income from Continuing Operations data on file, last reported at 102302000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 57.27% year-over-year to 102302000.0 in Q1 2026; TTM through Mar 2026 was 392534000.0, a 56.11% decrease from a year earlier, with the FY2025 full-year figure at 355279000.0, down 51.61% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 102302000.0, up from 114630000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for XENE reached as high as 19670000.0 in Q1 2022 and fell as low as 114630000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 58807117.65 across 5 years, with a median of 48462000.0 in 2023.
- Across the five-year window, Income from Continuing Operations plunged 140.53% in 2022 and fell 14.87% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 37439000.0 in 2022, then decreased by 19.51% to 44743000.0 in 2023, then tumbled by 46.81% to 65685000.0 in 2024, then slumped by 74.51% to 114630000.0 in 2025, then rose by 10.75% to 102302000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 102302000.0 in Q1 2026, 114630000.0 in Q4 2025, and 90896000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Xenon Pharmaceuticals | 5.72 Bn | 5.72 Bn | - | -102.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.30 Mn |
| Dec 31, 2025 | -114.63 Mn |
| Sep 30, 2025 | -90.90 Mn |
| Jun 30, 2025 | -84.71 Mn |
| Mar 31, 2025 | -65.05 Mn |
| Dec 31, 2024 | -65.69 Mn |
| Sep 30, 2024 | -62.79 Mn |
| Jun 30, 2024 | -57.92 Mn |
| Mar 31, 2024 | -47.93 Mn |
| Dec 31, 2023 | -44.74 Mn |
| Sep 30, 2023 | -48.46 Mn |
| Jun 30, 2023 | -47.46 Mn |
| Mar 31, 2023 | -41.73 Mn |
| Dec 31, 2022 | -37.44 Mn |
| Sep 30, 2022 | -37.15 Mn |
| Jun 30, 2022 | -31.16 Mn |
| Mar 31, 2022 | -19.67 Mn |
| Dec 31, 2021 | -27.60 Mn |
| Sep 30, 2021 | -15.45 Mn |
| Jun 30, 2021 | -22.11 Mn |